CS
ELDN icon

Credit Suisse’s Eledon Pharmaceuticals ELDN Stock Holding History

Credit Suisse’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-80
Closed -$72K – 4122
2016
Q2 		$72K Buy
+80
New +$88.3K ﹤0.01% 4108
2016
Q1 		– Sell
-124
Closed -$175K – 4038
2015
Q4 		$175K Buy
+124
New +$216K ﹤0.01% 3941

Other funds holding ELDN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's ELDN Position: Q3 2016 in Review

Credit Suisse sold out of Eledon Pharmaceuticals (ELDN) in Q3 2016, closing a stake of 80 shares — an estimated $72K sold.

Credit Suisse first reported a position in ELDN in Q4 2015 and held it in 2 quarters. The position peaked at $175K in Q4 2015. 44 funds tracked by Wall St. Rank hold ELDN as of Q3 2016.

  • Credit Suisse reported no remaining Eledon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Credit Suisse sold 80 Eledon Pharmaceuticals shares in Q3 2016, an estimated $72K.
  • Credit Suisse first reported a position in Eledon Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Credit Suisse's Eledon Pharmaceuticals position peaked at $175K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2016.

Based on Credit Suisse's 13F filing for Q3 2016, filed 15 Nov 2016.